The Comparison of Survival Rates of Postoperative Adjuvant Chemotherapies in The Stage III Gastric Cancer Patients.
10.12701/yujm.2006.23.2.193
- Author:
Eun Mi KIM
1
;
Se Won KIM
;
Sang Woon KIM
;
Sun Kyo SONG
Author Information
1. Department of Surgery, College of Medicine, Yeungnam University, Daegu, Korea. sksong@med.yu.ac.kr
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Survival rate;
Postoperative adjuvant chemotherapy;
Stage III gastric cancer
- MeSH:
Chemotherapy, Adjuvant;
Cisplatin;
Doxorubicin;
Drug Therapy*;
Etoposide;
Fluorouracil;
Gastrectomy;
Humans;
Leucovorin;
Lymph Node Excision;
Lymph Nodes;
Mitomycin;
Multivariate Analysis;
Neoplasm Metastasis;
Proportional Hazards Models;
Recurrence;
Stomach Neoplasms*;
Survival Rate*
- From:Yeungnam University Journal of Medicine
2006;23(2):193-204
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Various postoperative adjuvant chemotherapy regimens have been proposed for the patients with advanced gastric cancer. The majority of clinical trials have shown no significant difference in the survival benefit. The aim of this study was to compare the survival rates of postoperative adjuvant chemotherapies used in stage III gastric cancer patients who received curative gastrectomy. MATERIALS AND METHODS: Between 1990 and 1999, a survival analysis was performed in 260 patients who received curative gastric resection and postoperative adjuvant chemotherapy. The patients were divided into four groups according to the chemotherapeutic regimens received. The groups were: the F group: furtulon alone, FM group: furtulon and mitomycin, FAM group: 5-FU, adriamycin and mitomycin, FLEP group: 5-FU, leucovorin, etoposide and cisplatin. The survival rates were analyzed using the Kaplan-Meier method and the Cox proportional hazards model. RESULTS: There were no differences among the groups of patients with regard to tumor characteristics except for lymph node metastasis and the ratio of metastasis to lymph nodes. In the FLEP group, the ratio of metastasis to lymph nodes was higher than in the other groups. The five and ten year survival rates of F, FM, FAM and FLEP were 51.9%, 28.9%, 59.5%, 49.8%, 66.1%, 57.4% and 30.0%, 27.5%, respectively. The univariate analysis showed that age, Borrmann type, lymph node metastasis, ratio of metastasis to lymph nodes, postoperative adjuvant chemotherapy and recurrence were significant factors for survival. For the multivariate analysis, recurrence, age, Borrmann type, ratio of lymph node metastasis and lymph node dissection were independent prognostic factors; however, the postoperative adjuvant chemotherapy was not an independent prognostic factor. CONCLUSION: The FAM regimen was the most beneficial postoperative adjuvant chemotherapy for improved survival rates; the FM regimen was the second and the FLEP regimen was the last. In order to determine the effectiveness of postoperative adjuvant chemotherapy in stage III gastric cancer, well designed prospective studies including a surgery only group will be needed.
